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qual contribution to the article.a b s t r a c t
The X-ray diffraction and spectroscopic properties of 1-amino-4-hydroxy-9,10-anthraquinone (1-AHAQ),
a simple analogue of anthracycline chemotherapeutic drugs were studied by adopting experimental and
computational methods. The optimized geometrical parameters obtained from computational methods
were compared with the results of X-ray diffraction analysis and the two were found to be in reasonably
good agreement. X-ray diffraction study, Density Functional Theory (DFT) and natural bond orbital (NBO)
analysis indicated two types of hydrogen bonds in the molecule. The IR spectra of 1-AHAQ were studied
by Vibrational Energy Distribution Analysis (VEDA) using potential energy distribution (PED) analysis.
The electronic spectra were studied by TDDFT computation and compared with the experimental results.
Experimental and theoretical results corroborated each other to a fair extent. To understand the biolo-
gical efﬁcacy of 1-AHAQ, it was allowed to interact with calf thymus DNA and human breast adino-
carcinoma cell MDA-MB-231. It was found that the molecule induces apoptosis in this adinocarcinoma
cell, with little, if any, cytotoxic effect in HBL-100 normal breast epithelial cell.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Anthracycline drugs are chemotherapeutic agents containing a
planar hydroxy-9, 10-anthraquinone at the core of the molecule
that is in use for the treatment of various human cancers [1–3].
Although there is controversy regarding the exact mechanism of
action of these drugs as chemotherapeutics, various established
pathways of drug action such as intercalation into DNA base pairs,B.V. This is an open access article u
nthraquinone; DFT, Density
atural bond orbital; VEDA,
ial energy distributioninhibition of RNA transcription and DNA replication, inhibition of
topoisomerase II, induction of DNA cleavage, etc., were observed to
be associated with the interaction of such molecules with DNA
[4–10]. A few studies have also shown that the sugar moiety
present in these drugs facilitate recognition of cancer cells [9,10].
However, location of the sugar moiety on the aliphatic side chain
attached to the hydroxy-9, 10-anthraquinone unit in these mole-
cules makes them so expensive that most patients cannot afford to
practice these drugs. This is particularly true of cancer patients
belonging to the developing countries. Therefore, efforts are pre-
sently afoot to evaluate new but comparatively less expensive
substitutes of the known forms of these drugs. Through several
studies [11–20], we and others were able to develop less expensive
hydroxy-anthraquinone-mimetic drugs. Rossi and coworkers [17]
showed that two variant hydroxy-anthraquinones that do notnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Scheme 1. 1-Amino-4-hydroxy-9,10-anthraquinone.
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efﬁciency. Mitoxantrone, an amino hydroxy -anthraquinone, was
found to have better antineoplastic activity and produce lesser
toxic side effects than some of the popular anthracycline drugs
that are currently in use for treatment of various types of human
cancers [18].
In addition to afﬁnity of anthracyclines toward DNA, generation
of semiquinone intermediates due to the reduction of the quinone
unit by one-electron was found to play a critical role in their
chemotherapeutic efﬁcacy [21–23]. However, too much semi-
quinone formation is harmful [21–23]. The semiquinone reacts
with O2 thereby generating superoxide ion (O2–) and H2O2/OH
[24,25] that in turn cause various types of harmful effects, ren-
dering a study on redox behavior of such molecules important.
Earlier studies showed that planar anthraquinone unit present
in anthracycline drugs intercalates into DNA backbone by π–π
stacking and hydrophobic interaction [26,27]. It has been found
that intercalation is further stabilized through hydrogen bonding
between the bases of DNA and a drug molecule [28,29] which
makes the aspects of intra- and intermolecular hydrogen bonding
very important for this class of molecules. Deciphering the struc-
ture–activity relationship may lead to an introduction of new
medicines for a lot of diseases. Such an attempt has been made in
the present study so as to lead to a proper understanding of the
structure–selectivity relationship of anthracyclines which may
lead to bringing up a novel chemotherapeutic agent for the
treatment of cancer. Therefore, in the present study we established
the structure of 1-AHAQ from single crystal X-ray diffraction.
Computational and spectroscopic measurements were performed
to understand the electronic state of the molecule and to draw
knowledge on hydrogen bonding. In this context it is interesting to
note that three-dimensional structures are known only for a few
anthracyclines [30,31]. Hence, the three-dimensional structure of
1-AHAQ in the present study might be value-addition to this ﬁeld
of research.
Very recently we reported in detail the electrochemical prop-
erty of 1-AHAQ [32,33] and its copper complex and showed that
the molecule mimics the anthracycline drugs that are already in
practice. This was a pointer to us that 1-AHAQ might exhibit a
potential antitumor activity as anthracyclines owing to the simi-
larity in electrochemical behavior, an important parameter to de-
termine therapeutic efﬁciency. Hence, in the present study we
subjected 1-AHAQ to analysis cytotoxic potential so as to ﬁnd its
suitability as an anticancer agent. The molecule was allowed to
interact with ct DNA and the results correlated with its ability to
induce apoptosis in human breast adinocarcinoma cell MDA-MB-
231, sparing the normal breast epithelial cells HBL-100.2. Experimental
2.1. Materials
1-AHAQ (Scheme 1) (96%), purchased from Alfa Aesar, Ger-
many, was puriﬁed and characterized by methods described in our
recent reports [32,33]. The pH and ionic strengths of aqueous so-
lutions were maintained by using Hepes buffer and NaCl, respec-
tively (both were of AR Grade, Spectrochem, India). Methanol
(HPLC Grade, E-Merck, India), anhydrous acetonitrile (SRL, India),
and absolute ethanol (AR Grade) were used in experiments. All
other reagents used in the present study were of AR grade. Triple
distilled water was used to prepare aqueous solutions. A stock so-
lution of 1-AHAQ in ethanol of strength 103 mol L1 was prepared
by accurate weighing of the compound as it is almost insoluble in
water. For the experiments in aqueous media, the stock ethanol
solution of the compound was diluted quantitatively with water.All solutions of the compound were made just before the experi-
ment and stored in the dark as it is photosensitive. Calf thymus DNA
(ct DNA) (SRL, India) was dissolved in aqueous buffer and the purity
of it was checked from the ratio of the absorbance of the solution at
260 and 280 nm (A260/A280). The experimental solutions showed
that the ratio was in the range 1.8oA260/A280o1.9 which pro-
vided a good estimate of the purity of the DNA [34]. The con-
centration of experimental DNA solution was evaluated in terms
of nucleotide by considering ε260¼6600 M1 cm1 for ct DNA.
Single-stranded DNA was prepared by using the method as de-
scribed by Silva et al. [35].
2.2. Crystallographic analysis
A suitable single crystal of 1-AHAQ was subjected to diffraction
with graphite-monochromated Mo-Kα radiation (λ¼0.71073 Å).
The evaluated experimental data was integrated by SAINT [36] and
absorption corrections were done using SADABS. Structure was
resolved using SHELXS 97 adopting Patterson method [37] which
was then followed by consecutive Fourier and difference Fourier
synthesis. In the present study full-matrix least-squares reﬁne-
ment was done on F2 by via SHELXL 97 [37] with the anisotropic
displacement parameters for all the non-hydrogen atoms [38].
During reﬁnement, data were subjected to calculations adopting
SHELXL 97, SHELXS 97, PLATON v1.15, ORTEP-3v2 and WinGX
v1.80 [39–41]. Some important parameters of crystallographic
analysis and structure and bonding are summarized in Tables 1
and S1 (Supporting information), respectively.
2.3. Computational methods
Hartree-Fock (HF) and Density Functional Theory (DFT), for
example B3LYP and PBEPBE [42–44], were applied to determine
the fully unconstrained geometry optimization and energy calcu-
lation on the molecule. To incorporate the effect of the solvent,
conductors like polarized continuum medium (CPCM) [45–48]
were employed.
Vibrational Energy Distribution Analysis (VEDA) 4.0 [49] was
used to calculate potential energy distribution (PED). The modes of
vibration of the molecule were assigned precisely by using PED
values and visual check up with Gauss View 4.1. Natural bond
orbital analysis (NBO) at B3LYP/6-31þG (d, p) was applied to re-
cognize orbital interactions, natural atomic charges and
Table 1
Crystallographic data and reﬁnement details for 1-amino-4-hydroxy-9,10-
anthraquinone.
Formula C14 H9 N O3
Formula weight 239.22
Crystal system Triclinic
Space group P1
a (Å) 3.8012(1)
b (Å) 9.6978(3)
c (Å) 14.3666(5)
α (deg) 90
β (deg) 96.671(2)
γ (deg) 90
V (Å3) 526.01(3)
Z 2
Dcalc (g/cm3) 1.510
μ (mm1) (MoKα) 0.108
Temperature (K) 293
Total Uniq. Data R(int) 6281, 2789, 0.018
Observed data I 42s(I) 2524
R, wR2, S 0.0300, 0.0818, 1.05
Min. and Max. Resd. Dens. [e/ Å3] 0.15, 0.12
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with the help of NBO 3.1 [50–52]. In this study, NBOs were ﬁrst
deﬁned for each covalent bond, lone pair, and anti-bonding orbital
by using the molecular orbitals obtained by quantum chemical
calculations [53] estimated by using second order perturbation
theory. The expression of stabilization energy E(2) associated with
NBO Fock matrix element for each donor and acceptor NBO (i and
j, respectively) can be shown as
E q
F i j
2 E
,
1i j i
ij
2
( ) ε ε=∆ =
( )
( )−
where qi¼donor orbital occupancy, εi and εj¼diagonal ele-
ments and F(i,j)¼off diagonal NBO Fock matrix element. The
quantum chemical computations were done with Gaussian 09
package [54].
2.4. Spectroscopic and electrochemical studies
FTIR in the range of 500–4000 cm1 was measured in Perkin
Elmer RX-I spectrophotometer by using KBr pellets. UV–vis studies
were done using the spectrophotometer, Model: MECASYS OPTI-
ZEN POP, South Korea. Electrochemical measurements were car-
ried out by using a three- electrode system and the potentiostat,
Digi-Ivy, Model DY2312. In this case the working electrode was a
glassy carbon electrode having surface area 0.07065 cm2, the re-
ference electrode was Ag/AgCl, saturated KCl whereas the counter
electrode was a platinum wire. During these experiments tem-
perature was maintained at 298.15 K with the help of a circulating
water bath. To avoid the effect of dissolved oxygen in the elec-
trochemical studies all solutions were degassed before the ex-
periment for 45 min by using high-purity argon.
2.5. Cell culture
The MDA-MB-231 human breast adinocarcinoma cells and
HBL-100 normal breast epithelial cells were provided by National
Center for Cell Science (NCCS), Pune, India. DMEM medium (Sig-
ma–Aldrich, St. Louis, MO, USA), supplementd with 10% fetal bo-
vine serum (Gibco), was used to culture the cells. Penicillin
(100 U/mL) and of streptomycin (100 μg/mL) (Gibco) were used as
antibiotics. The cells were cultured in 96 well plates in a
CO2 incubator (Thermo Scientiﬁc, USA). The culture conditions
included 37 °C, humidiﬁed atmosphere and 5% CO2. Care was ta-
ken to use cells belonging to passage 15 or less.
2.6. Cytotoxicity assay (MTT assay)
For the cytotoxicity assay 1-AHAQ was dissolved in DMSO. The
concentration was in the range 20–200 μM. The MDA-MB-231
cells were seeded at 5103 cells per well in 200 μL of fresh cul-
ture medium. The test substance was added to the wells 24 h after
seeding DMSO solution was treated as solvent control. The cell
viability/growth inhibition was assessed using the MTT [3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide] meth-
od, according to Mosmann [55]. The MTT solution, 5 mg/mL, was
prepared in phosphate-buffered saline (PBS). After incubation for
24 h and 48 h, 20 μL of MTT solution was added to each well. The
plates were incubated for 4 h at 37 °C in dark. The reaction re-
sulted in formation of purple formazan, which was dissolved in of
100 μL of DMSO added to each well. The OD was read in a 96-well
plate reader (Bio-Rad, Hercules, CA, USA) at 570 nm (measure-
ment) and 630 nm (reference). The experiments were conducted
in triplicates. and the data were used for calculating the mean
percentage inhibition. The following formula was used:Percentage inhibition
Mean OD of untreated cells control Mean OD of treated cells treated 100
Mean absorbance of untreated cells control
( ) ( )= [ − ] ×
( )
A standard curve was prepared by plotting % inhibition against
concentration, and the concentration of the test substance which
reduced the viability to 50% (IC50) was deduced.2.7. Acridine orange (AO) and ethidium bromide (EB) staining
The morphological changes in cells that would reveal if cell
death occurs via apoptosis or necrosis were analyzed adopting
acridine orange (AO) and ethidium bromide (EB) staining [56].
MDA-MB-231 cells were seeded into the wells of 6 well plate at an
initial density of 5105 cells per well. After attachment the cells
were exposed to 1-AHAQ at its 24 h IC50 concentration. After in-
cubation the cells were stained with AO - EB solution (AO –
3.8 μM; EB – 2.5 μM of EB in PBS; 25 μL to each well) and ex-
amined in a ﬂuorescent microscope (Carl Zeiss, Jena, Germany) at
450–490 nm. Three hundred cells per well were counted in tri-
plicate. The cells were scored as viable, apoptotic or necrotic as
judged by based on the morphological changes as revealed in the
color, morphology of nuclei and integrity of the membrane [56]
the cells were assigned as viable, apoptotic or necrotic. From this
data percentages of cells in apoptosis and necrosis were calculated.
Cells reﬂecting morphological changes of interest were
photographed.2.8. Hoechst 33528 Staining
For assessment of nuclear morphological changes MDA-MB-
231 cells were cultured in 6-well plates and treated with the 24 h
IC50 concentration of 1-AHAQ. The cells were stained for 5 min
with an aqueous solution of Hoechst 33258 (1 mg/mL) [57]. A drop
of cell suspension was loaded onto a glass slide and covered with a
coverslip. At random 300 cells were observed at 400 in a
ﬂuorescent microscope (Carl Zeiss, Jena, Germany). The cells were
counted in three ﬁelds each, and classiﬁed as normal or patholo-
gical, and the data were converted to the respective percentages.
Fig. 1. X-ray crystallographic structure of 1-AHAQ (per unit cell two identical molecules are present).
Table 2
Hydrogen bond lengths [Å] and angles [deg] for 1-amino-4-hydroxy-9,10-
anthraquinone.
D-H…A D-H H….A D….A ∠D-H….A
N23-H24……O21 0.90(3) 1.96(3) 2.662(3) 134(2)
N23-H25…….O21 1.00(4) 2.11(4) 3.078(3) 163(3)
O26-H27…….O22 0.99(3) 1.62(4) 2.507(3) 146(3)
D is donor and A is acceptor.
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3.1. Structure of 1-AHAQ from crystallographic methods
Analysis of single crystal structure of 1-AHAQ showed that itFig. 2. Optimized molecular structure of 1-amino-4-hydroxycrystallizes in the triclinic space group P1 (Table 1) in which two
identical molecules are present per unit cell (only one molecule is
shown in Fig. 1 as the two are identical). The bonding parameters
are shown in Table S1 (Supporting information) from which it is
clear that C7–O22, C8–O21, C11–O26, C14–N23 and N23–H24 bond
lengths are considerably shorter than typical single C–O (1.38–
1.42 Å), C–N (1.44-1.47 Å) and N–H (1.00) bonds while the O26–
H27 bond length (0.99 Å) is longer than typical single O–H (0.94–
0.96) bonds. The two hydrogen bonds are shown in Fig. 1 (Table 2).
These two hydrogen bonds of 1-AHAQ are connected by N23–
H24….O21 (2.662 Å, 134o) and O26–H27…O22 (2.507 Å, 146o)
(Table 2) which is comparable to that observed in an earlier study
by Zhu et al. [58].-9,10-anthraquinone using B3LYP/6-31þG(d,p) protocol.
HOMO-1
LUMO+1
E
E
- 0.25876 a. u.
=
=
E =
- 0.05181 a. u.
0.20695 a. u.
EHOMO
LUMOE
-0.20635 a. u.
-0.10886 a. u
=
=
E = 0.09749 a. u.
Fig. 3. The isodensity plot of HOMO, LUMO, HOMO-1 and LUMOþ1 for 1-amino-4-hydroxy-9,10-anthraquinone.
P. Mondal et al. / Biochemistry and Biophysics Reports 4 (2015) 312–3233163.2. Structure of 1-AHAQ deduced from computational methods
Optimized structure of 1-AHAQ is shown in Fig. 2 for which the
minimum energy values were observed as 814.515, 819.423
and 818.477 a.u. for HF, B3LYP and PBEPBE, respectively. The
difference in the values of energy was observed to be dependent
on the methods of calculation. Thus, the absolute value of elec-
tronic energy depends on the methods of calculation. The most
important bonding parameters are shown in Table S1 (Supporting
information). As found in the single crystal structure of the mo-
lecule, hydrogen bonding between O21 and H24 and O22 and O27
were established in this case which is discussed in NBO analysis
(Section 3.5.). Comparison of the experimental with theoretical
bonding parameters showed a very slight deviation between the
two which is probably due to the fact that computational studies
were carried out on an isolated gaseous molecule whereas the
experimental results were evaluated in the solid state.
The frontier molecular orbital (FMO) of a molecule consists of
highest occupied molecular orbital (HOMO) and lowest un-
occupied molecular orbital (LUMO). A consideration of such orbi-
tals is very much helpful in determining the way in which a mo-
lecule such as 1-AHAQ molecule interacts with a biological mac-
romolecule such as DNA [59]. The chemical reactivity of a mole-
cule in terms of electronic behavior is related to the energy gap in
FMO since HOMO acts as an electron donor while LUMO acts as an
electron acceptor. The energy gap between HOMO and LUMO in
the present study was determined as 0.097 a.u. The isodensity plot
of FMOs are shown in Fig. 3 fromwhich it is clear that HOMO looks
as delocalized p-type and LUMO as localized p-type.
3.3. Theoretical and experimental IR spectra of 1-AHAQ
VEDA [50] with PED analysis was employed to analyze theo-
retical vibrational spectrum of 1-AHAQ [33]. In this method, somenormal modes are extended over the entire molecule and PED is
accounted for certain levels [33]. This enables one to describe the
contribution to the movement of a given group of atoms in a
normal mode quantitatively [33]. Data from theoretical IR spectral
analysis was compared with experimental results to see whether
1-AHAQ is in the ground state or in any transition state. For
transition state of a molecule at least one imaginary frequency
should be present in the theoretical studies. However, in the
present calculation all the theoretical IR bands are positive which
means that 1-AHAQ is in the ground state. This further supports
the structure of 1-AHAQ obtained both from the crystallographic
and density functional methods. 1-AHAQ contains 27 atoms and its
optimized molecular structure exhibits 75 fundamental vibrations
which are IR active, out of which 26 are stretching, 25 are bending
and 24 are torsion. The computed vibrational frequencies are over-
estimated and scaled 0.9613 for B3LYP/6-31þ G (d, p) level of
computation [49]. IR frequency and intensity, PED and description
about the modes of vibration for 1-AHAQ are shown in Table S2
(Supporting information). Comparing the theoretical and experi-
mental bands (Table S2 and Fig. S1) (Supporting Information) it
may be concluded that both the results corroborate excellently in
the region below 3000 cm1. However, a deviation appears be-
tween theoretical and experimental IR intensities in the region
3000 cm1 and above which may be due to the hampering of
crystal ﬁeld spectra [60].
3.4. UV–vis spectroscopy of 1-AHAQ
In 30% ethanol the absorption spectra of 1-AHAQ show four
peaks at 248, 288, 530 and 565 nm [Fig. S2 (Supporting informa-
tion)]. In aqueous media 1-AHAQ exists in different tautomeric
forms due to keto-enol tautomerism which remain in very rapid
equilibrium [61]. The π–π* and n–π* transitions of such tautomeric
structures result in the above-mentioned absorption peaks [33].
Table 3
The experimental and theoretical λmax of bands of 1-amino-4-hydroxy-9, 10- anthraquinone along with the molecular orbitals involved in the transitions.
Experimental band (ε, dm3 mol1 cm1) TD-DFT peaks (oscillator strength) Contribution
565 499 (0.1633) HOMO-LUMO
530 402 (0.0006) (HOMO-1)-LUMO
288 287 (0.055) HOMO-(LUMOþ2)
288 278 (0.1205) (HOMO-3)-(LUMOþ2)
(HOMO)-(LUMOþ3)
(HOMO)-(LUMOþ5)
(HOMO-5)-(LUMO)
(HOMO-6)-(LUMO)
248 235 (0.3275) (HOMO-3)-(LUMOþ1)
(HOMO-3)-(LUMOþ2)
(HOMO-2)-(LUMOþ1)
(HOMO-2)-(LUMOþ2)
(HOMO)-(LUMOþ3)
P. Mondal et al. / Biochemistry and Biophysics Reports 4 (2015) 312–323 317TDDFT method was applied to characterize the nature of orbitals
involved in such transitions and to justify the experimental ﬁnd-
ings with theoretical values. The theoretical and experimental
absorption spectra of 1-AHAQ are shown in Fig. S2 (Supporting
information) and the absorption maxima λmax and nature of dif-
ferent atomic orbitals in the molecular orbitals associated with the
transitions are shown in Tables 3 and S3 (Supporting information),
respectively. Theoretical results established that several atomic
orbitals combine to produce a molecular orbital. By applying DFT
procedure, the molecular orbitals involved in transitions were
determined and are shown in Fig. 4. From Fig. 4 it is clear that
HOMO is due to π-orbitals present in the ring while LUMO is of π*
character. The study suggests that theoretical absorption spectra
corroborate the experimental result of the molecule very nicely.
3.5. NBO analysis
Intermolecular recognition is a key process for the interaction
of a molecule with biological systems. The strength of intra- and
intermolecular weak interactions including aromatic stacking,
binding and intercalation, Van der Waals interactions, hydrogen
bond formation, etc., are closely related to the biological activity of
a molecule [59]. Such interactions can be explained by NBO ana-
lysis as it provides knowledge about the interactions in both ﬁlled
and virtual orbitals of a molecule. The values for the second order
perturbation energy (E(2)) associated with NBO Fock matrix ele-
ment are mentioned in Table S4 (Supporting information). The
large values of E(2) (158.71, 108.00, 93.24 and 80.46 kcal/mol)
[Table S5 (Supporting information)] are indicative of very strong
hyperconjugative interactions in the aromatic ring system of
1-AHAQ. The hyperconjugative interaction and electron density
delocalization of lone pairs from O22 to the antibonding orbital of(LUMO) (LUMO +1) (LUMO
(HOMO) (HOMO-1) (HOMO
Fig. 4. Important molecular orbitals involved in electronicO26–H27 in the O26–H27…..O22 moiety [LP(1) O22-BD*(1) O26–H27,
LP (2) O22-BD*(1) O26–H27] were evaluated in the present study
[Table S4 (Supporting information)]. In the same way, lone pairs of
O21 were observed to be delocalized to the antibonding N23–H24 s*
orbital [LP(1) O21-BD*( 1) N23–H24 and LP(2) O21-BD*( 1) N23–
H24] in N23–H24…O21 moiety. The intramolecular charge transfer
in both cases clearly indicates the presence of the intramolecular
hydrogen bond (IHB). The geometrical parameters found in the
optimization process [Table S1 (Supporting information)] also fa-
vor the presence of hydrogen bonds in O22…H27–O26 and O21….
H24–N23 moiety.
In order to derive knowledge about hydrogen bonding between
(O22 ...H27–O26) and (O21 ...H24–N23), population analysis was done
in MO62X DFT protocol with 6-311þ g (d,p) basic set in conductor
such as polarized continuum medium (CPCM). Global- hybrid
meta GGA MO62X DFT protocol implemented by Truhlar group
[62,63] was ﬁtted to evaluate medium range dispersion interac-
tions. Wiberg bond indices [64] are a measure of the bond inter-
action between two atoms and function as a nominal bond order
which were determined by using NBO analysis. In the present case
it established an overlap involving a hydrogen atom in O22…H27–
O26 and O21….H24–N23 moieties, which means that the hydrogen
bonds are not purely electrostatic in character. Wiberg bond in-
dices for the two hydrogen bonds were observed as 0.0926 and
0.0215 for O22...H27 and H24….O21, respectively, which clearly
shows that O22...H27 is a strong hydrogen bond while H24….O21 is a
weak hydrogen bond. The information about the strength of hy-
drogen bonds obtained from the Wiberg bond indices justiﬁes the
information on hydrogen bonds obtained from the crystal-
lographic and energy-optimized results of the present molecule.+2) (LUMO+3) (LUMO+5)
-2) (HOMO-3) (HOMO-5)
transitions of 1-amino-4-hydroxy-9,10-anthraquinone.
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In our very recent studies [32,33] we observed that 1-AHAQ
undergoes single step quasi-reversible reduction by two electrons
in aqueous media at neutral pH (7.0). The electrochemical aspect
of the molecule at physiological pH (7.4) is an important step for a
molecule in determining its biological action. However, in earlier
studies [32,33] the electrochemical reduction of 1-AHAQ was not
studied in aqueous buffer at physiological pH (7.4) and that is the
reason why in the present study we report the redox behavior of
1-AHAQ in aqueous solution at pH 7.4. This shows a quasir-
eversible two-electron reduction at –665 mV corresponding to the
reduction of quinone to quinone dianion [Fig. S3 (Supporting in-
formation)]. The formal reduction potential was observed as
650 mV. Chronocoulometric measurements were done to de-
termine the number of electrons concerned in this reduction. The
quinone dianion generated in this process is stabilized by solvent
water molecules through hydrogen bonds thereby making the
process irreversible [32]. However, with the increase in scan rate
the reduction becomes increasingly reversible which might be due
to the fact that at higher scan rate quinone dianion gets smaller
time to be stabilized by solvent water molecules. In aqueous
media, anthracycline drugs adriamycin, daunorubicin, idarubicin,
etc., [65–68] also undergo two-electron reduction, as observed in
case of 1-AHAQ, that leads to a similarity in electrochemical be-
havior in such media. We observed that the electrochemical
property of the present molecule is governed by several factors
such as solvent polarity, existence of acidic or basic species in the
media, character of supporting electrolyte, intra- and inter-
molecular hydrogen bonding, homogeneous chemical reaction,
etc., in both aqueous and non-aqueous media [32]. This property
of 1-AHAQ exactly mimics the established anthracycline drugs in
every step of the electrochemical actions [32] which raises the
expectation that it might exhibit a potential antitumor activity.
3.7. Investigation on the interaction of 1-AHAQ with calf thymus
DNA
In aqueous media containing 2% ethanol at physiological pH
(7.4), in the presence of 120 mM NaCl, the absorption spectrum of
1-AHAQ was as shown in Fig. 5a which exhibits an absorption peak
at 530 nm. To study the 1-AHAQ–DNA interaction, a set of ex-
perimental solutions was prepared consisting of a ﬁxed con-
centration of 1-AHAQ ([1-AHAQ]¼20 mM) and variable con-
centrations of ct DNA. The absorbance of such solutions wereFig. 5. (a). Absorption spectra of 1-AHAQ (20 mM) in the absence (Curve-1) and in the pr
120 mM, 25 °C. (b). Double reciprocal plot, (A0/A–A0) vs. 1/[DNA], of 1-AHAQ–calf thymmeasured at 530 nm and applied to determine the binding para-
meters. The change in absorption spectra of the compound with
increasing amount of DNA is shown in Fig. 5a which clearly in-
dicates a hypochromic effect along with a slight bathochromic
shift with the increase in concentration of DNA. These shifts were
produced as the result of the electronic interaction owing to the
intercalation of the compound chromophore into DNA backbone
[68–71]. In order to check whether hypocromism in the absorption
spectra of 1-AHAQ upon addition of DNA might be related to a
precipitation of 1-AHAQ rather than to its interaction with DNA,
different sets of solutions containing a constant concentration of
1-AHAQ (20 mM) and different concentrations of ethanol [Fig. S4
(Supporting information)] were prepared and UV–vis spectra were
measured. From this ﬁgure it is clear that in the presence of dif-
ferent concentrations ethanol, the UV–vis spectra and hence the
absorbances of 1-AHAQ at 530 nm do not alter signiﬁcantly. Thus
it may be said that hypocromism in the UV–vis spectra of 1-AHAQ
in DNA interaction study was due to the interaction of 1-AHAQ
with DNA but not due to a precipitation of the molecule in the
reaction media. In our very recent study [72], by using cyclic
voltammetry as monitoring technique we also established that
1-AHAQ interacts with DNA which results in a decrease in the
reduction peak current of 1-AHAQ under the similar experimental
condition as we used in the present study. In that study [72] we
also observed no precipitation of 1-AHAQ in the reaction media
since a precipitation of an experimental molecule (1-AHAQ) can
cause a great disturbance in the electrochemical setup and it was
not possible to carry out a DNA interaction using cyclic
voltammetry.
Depending on the change in absorbance of 1-AHAQ at 530 nm
upon its interaction with DNA, the apparent binding constant (K)
was evaluated by using Eq. (2) [73].
A
A A
1
K DNA 2
0
0
b b−
= ε
ε −ε
+ ε
ε −ε [ ] ( )
where A0 and A¼absorbances of 1-AHAQ in the absence and in
the presence of DNA at 530 nm; ε and εb ¼molar extinction
coefﬁcients of 1-AHAQ and DNA.1-AHAQ, respectively.
A plot of A0/(A–A0) vs. the inverse of the concentration of DNA
according to Eq. (2) (Fig. 5b) is a straight line which produced K as
(1.0970.11)104 M1.
The outcome of the spectrometric studies on 1-AHAQ–DNA
interaction was also analyzed using non-linear method assuming
the equilibrium as described in Eq. (3) [12,14–16,74–78].esence of different calf thymus DNA concentrations (Curve- 2–7). pH¼7.4, [NaCl]¼
us DNA interaction; [1-AHAQ]0 ¼ 20 mM, pH¼7.4, [NaCl]¼120 mM, 25 °C.
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The equilibrium constant for the dissociation of DNA.1-AHAQ
species may be represented as:
⎡⎣ ⎤⎦⎡⎣ ⎤⎦
⎡⎣ ⎤⎦K
1 AHAQ DNA
DNA. 1 AHAQ 4
d =
−
− ( )
5
K
1 AHAQ DNA. 1 AHAQ DNA DNA. 1 AHAQ
DNA. 1 AHAQd
0 0[ ] [ ] ]
( )=
{ − − − }{[ −[ − ]}
[ − ]
where, [1-AHAQ]0¼concentration of 1-AHAQ which was constant
in all the titration mixtures and [DNA0]¼concentration of DNA in
the solution. The apparent binding constant may then be de-
termined by taking the inverse of the dissociation constant (i.e.,
K¼1/Kd). In the present study, the concentration of 1-AHAQ was
20 mM while that of DNA was reserved 20–25-fold higher than the
compound. Basic assumption of the present study is that the DNA
concentration must be much greater than the concentration of the
compound (1-AHAQ). Now, if C0¼[1-AHAQ]0¼20 mM while
CD¼[DNA0]¼DNA concentration in the solution, then
K
C DNA. 1 AHAQ C DNA. 1 AHAQ
DNA. 1 AHAQ 6d
0 D= { −[ − ]}{ −[ − ]}
[ − ] ( )
The change in absorbance of 1-AHAQ owing to the addition of
DNA can be given as ΔA¼(A0–A). ΔAm is the same parameter
when 1-AHAQ is totally combined to DNA. During the entire ex-
periment, both free 1-AHAQ and its bound form with DNA (i.e.,
1-AHAQ.DNA) contribute to the observed absorbance. Thus, ΔA
may be expressed as (εcfi–εbcbi) where cbi corresponds to 1-AHAQ.
DNA concentration while cfi is the concentration of free 1-AHAQ in
the experimental solution. ε and εb are the molar extinction
coefﬁcients of 1-AHAQ and DNA.1-AHAQ, respectively.
Therefore, (ΔA/ΔAm) denotes the fraction of 1-AHAQ bound to
DNA. Hence, one gets (ΔA/ΔAm)C0 ¼ [DNA.1-AHAQ]. Then Eq.
(6) becomes
⎡
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ΔFig. 6. (a) Double reciprocal plot of 1-AHAQ – calf thymus DNA interaction using UV–v
isotherm of 1-AHAQ and calf thymus DNA and corresponding non-linear ﬁt using UV–v⎛
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Experimental data from the binding studies were analyzed
according to Eq. (8) by using the method of least square ﬁt to
determine Kd and, hence, K. However, the evaluation of Kd using
this method requires the value ofΔAm which was determined by a
double reciprocal plot (Fig. 6a) of 1/ΔA vs. 1/(CD–C0) according to
Eq. (9) [12,14–16,74–78]. Using this method (Fig. 6a) the value of
Kd was also evaluated.
K1
A
1
A A C C 9
d
m m D 0( )Δ = Δ + Δ − ( )
Fig. 6b shows the binding isotherm of 1-AHAQ with DNA from
which the apparent binding constant was determined by using Eq.
(8) as (1.2070.08)104 M1. The double reciprocal plot (Fig. 6a)
produced the apparent binding constant as (1.5670.10)
104 M1. Using the plot of A0/(AA0) against the inverse of [DNA]
(Fig. 5b), K was obtained as (1.0970.11)104 M1 (summarized
in Table 4). Comparing the values of K, it is clear that three
methods for the determination of K correlate excellently. The plot
of (ΔA/ΔAm) vs. the mole ratio of 1-AHAQ to DNA bases [Fig. S5
(Supporting information)] produced two straight lines intersecting
with each other at particular point which actually gives the bind
site size or binding stoichiometry (n) in terms of DNA bases bound
per molecule of 1-AHAQ [12,14–16,74–79]. In the present study ‘n’
was established as (6.5270.42) bases, i.e., (3.2670.21) base pairs.
It was then used to ﬁnd the intrinsic binding constant K′, i.e.
(Kn) which was observed as (1.201046.52), i.e.,
(7.8270.16)104 M1. In a very recent work [72] by using cyclic
voltammetry and ethidiumbromide displacement assay we
showed that 1-AHAQ intercalates DNA with an intrinsic binding
constant in the order of 104 M1 which justiﬁes the method of
present measurement.
Another important double reciprocal method used in an earlier
study [80] was employed in the present study to ﬁnd K by using
Eq. (10).
1
f
1
1
K DNA 10
= +
[ ] ( )
where f¼fraction of total 1-AHAQ bound¼Cb/C0¼[DNA.1-AHAQ]/
[1-AHAQ]0 ¼ {(ΔA/ΔAm)C0}/ C0¼(ΔA/ΔAm). [DNA] is con-
centration of DNA in bases in the experimental solution. It isis spectroscopy; [1-AHAQ]0 ¼ 20 mM, pH¼7.4, [NaCl]¼120 mM, 25 °C. (b). Binding
is spectroscopy; [1-AHAQ]0¼20 mM, pH¼7.4, [NaCl]¼120 M, 25○C.
Table 4
Comparison of binding parameters obtained from different ﬁtting models.
Apparent binding constant (K) (M1) Binding site size (n)
(Bases)
Intrinsic Binding Constant K′
¼(Kn) (M1)
Double reciprocal plot
using Eq. (2)
Non linear ﬁt analysis
using Eq. (8)
Double reciprocal plot
using Eq. (9)
Double reciprocal plot
using Eq. (10)
(1.0970.11)104 (1.2070.08)104 (1.5670.10)104 (1.5070.12)104 (6.5270.42) (7.8270.16)04
Fig. 7. Absorption spectra of 1-AHAQ in the absence (solid line) and presence
(dotted line) of single stranded ct DNA in phosphate buffer at pH 7.4. [1-AHAQ] ¼
30 mM, [Phosphate Buffer]¼50 mM, [NaCl]¼120 mM, [ss DNA]¼80 mM, 298.15 K.
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experiments where the free DNA is present in large excess in
comparison to that of the compound tested [79]. The present
study followed this condition as we mentioned above, and that is
the reason why such a double reciprocal plot [Fig. S5 (Supporting
information)] should be useful in our case. Using the method, K
was evaluated as (1.5070.12)104 M1 which corroborate nicely
with the values observed from other methods (Table 4). A com-
parison of the present results with an earlier study [81] it can be
said that intrinsic and apparent binding constants obtained in the
present study are very close to that reported for mitoxantrone and
other anthracycline drugs [81]. Oyagaet al. [59] showed that a
strong binding of a molecule with DNA is a measure of cytotoxicity
at cellular level which makes 1-AHAQ to be important in the area
of anthracycline research. Further, the interaction of this categoryFig. 8. (a) MTT assay for 1-AHAQ for 24 h and 48 h in MDAMB 231 celof compounds with DNA is also a signiﬁcant step in their action as
drug [4–8]. Thus, considering the binding afﬁnity of the present
molecule with DNA, one may expect that 1-AHAQ might be a
potential antitumor agent like established anthracyclines.
3.8. Mode of interaction of 1-AHAQ with DNA
The nature of 1-AHAQ–DNA interaction was established by
carrying out binding studies of 1-AHAQ with single-stranded ct
DNA under the similar experimental conditions as mentioned
above. An aliquot containing 1-AHAQ and single-stranded ct DNA
(ss DNA) was prepared and UV–vis spectrum was measured. Fig. 7
shows the absorption spectra of 1-AHAQ and 1-AHAQ – ss DNA
mixture which shows that the addition of ss DNA does not bring a
signiﬁcant change in the intensity of the peak at 530 nm. This
clearly suggests that the chance of groove binding between DNA
and 1-AHAQ is negligible. Thus, the hypochromic effect found in
the interaction of 1-AHAQ with double-stranded ct DNA is deﬁ-
nitely due to intercalation of the compound into DNA base pairs
[Scheme SI (Supporting Information)].
A competitive binding study involving 1-AHAQ, double-stran-
ded ct DNA and ethidium bromide (EB), an established DNA in-
tercalator, was also done to establish the intercalation mode by
monitoring ﬂuorescence of the mixture in our very recent study
[72]. The study conﬁrmed that 1-AHAQ intercalates into the dou-
ble-stranded DNA by replacing EB [72]. As mentioned above the
intercalation of this class of molecules into DNA base pairs plays a
key role in their drug action. Intercalation of 1-AHAQ into DNA
base pairs and binding afﬁnity of the current molecule with DNA
being comparable to anthracycline drugs clearly suggest that the
planar 9,10-anthraquinone unit of the molecule probably plays the
role in its biological action. This may raise the hope that 1-AHAQ
might be a potential antitumor agent like established anthracy-
clines. In order to see if these results lead to an induction of
apoptosis in cancer cells, 1-AHAQ was applied to MDA-MB-231
breast adinocarcinoma cells and the outcomes of the entire studies
were correlated.ls. (b) MTT assay for 1-AHAQ for 24 h and 4 8 h in HBL-100 cells.
Table 5
Inhibitory concentration of 1-AHAQ against MDA-MB-231 breast adinocarcinoma
and HBL-100 breast epithelial cells.
Cell line 1-AHAQ
Inhibitory rates
(%)
Concentration in (mM)
24 h 48 h
MDA-MB-231 (breast adinocarcino-
ma cells)
50 20070.02 14070.03
HBL-100 (breast epithelial cells) 20 20070.05 20070.02
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1-AHAQ was applied to MDA-MB-231 breast adinocarcinoma
and HBL-100 breast epithelial cell lines and its inhibitory effect at
different concentrations (20-200 mM) and time intervals (24 and
48 h) were investigated adopting MTT assay (Fig. 8). MTT is con-
verted into purple-colored formazon product in cells with viable
mitochondria whereas dead or dying cells lose this ability. Thus
the color of the formazon and the subsequent solution in DMSO is
indication of the metabolic viability or otherwise of the cells. It
was observed that 1-AHAQ is cytotoxic to MDA-MB-231 breast
adinocarcinoma cells in a manner dose-dependent and little if any
on HBL-100 breast epithelial cells. Fig. 8 and Table 5 show the
inhibitory rates and corresponding concentrations at which
1-AHAQ is cytotoxic to the adinocarcinomatous MDA-MB-231
cells. Results in Table- 5 clearly indicate that 1-AHAQ was able to
cause 50% growth inhibition of the cancer cells at 200 mM con-
centration when incubated for 24 hours and at 140 mM con-
centration when incubated for 48 hours whereas it had almost no
effect on normal cells with inhibition being only 20% at 200 mM
when incubated for 24 hours as well as 48 hours. Thus 1-AHAQ
behaves as a potential anticancer agent.
3.10. AO/EB staining
Apoptosis is a highly regulated physiological cell death. The
cells undergoing this mechanism of death exhibit very speciﬁc
morphologies. The affected cells shrink to small size, the nucleus
also dereases in size accompanied by condensation of chromatinFig. 9. The effect of 1-AHAQ on MDAMB 231 cells with Acridine orange and ethidium bro
231 cells after 24 h incubation with 1-AHAQ. (b) Relative percentage of morphological
necrosis as compared with the control cells after 24 h incubation.and fragmentation of DNA, blebbing of cell membrane, and
apoptotic body formation. If treatment of MDA-MB-231 adino-
carcinoma cells with 1-AHAQ results in these indicators of apop-
tosis was assessed adopting AO/EB staining. We adopted dual
staining, AO and EB. AO was excited at 500 nm (DNA) and emits at
526 nm; EB is excited at 510 nm and emits at 595 nm. Since we
used a Zeiss ﬂuorescent microscope we used the nearest UV ﬁlter
set 09 which excites between 450 and 490 nm and allows emis-
sion at 515 nm. In this staining method AO renders both live and
dead cells to ﬂuoresce, live in green and dead in shades of red. EB,
on the other hand permeates only cells in which the membrane
integrity has been lost, i.e., dead/unviable cells, and ﬂuoresces in
shades of red. Thus, EB permeates dead cells which ﬂuoresce or-
ange-red which are super-imposed to the red ﬂuorescence of AO.
Live cells allow only AO to permeate and ﬂuoresce green. Cytolo-
gical changes observed in the treated cells are classiﬁed into Four
different nuclear features and ﬂuorescence patterns are discern-
able on staining with AO and EB: (i) in viable cells nuclei are
normal, so ﬂuoresce green; (ii) cells in an early phase of apoptosis
in which the nuclei are condensed ﬂuoresce orange-green; (iii)
cells in a late phase of apoptosis , the chromatin is highly con-
densed or fragmented and ﬂuoresce orange to red; and iv) cells
undergoing necrotic death do not show fragmentation of chro-
matin and ﬂuoresce orange to red. In 1-AHAQ-treated cancer cells
all these morphological changes could be observed. The data in
respect of treatment with IC50 concentration of 1-AHAQ for 24 h
are presented in Fig. 9a, which reveal that apoptotic morphology
was in preponderance but there were a few cells with necrotic
morphologies also. The data presented in Fig. 9b reveal that
1-AHAQ is efﬁcient in inducing apoptotic death in MDA-MB-231
breast adinocarcinoma cell rather selectively.
3.11. Hoechst staining
Hoechst 33528 staining speciﬁcally reveals morphological chan-
ges in the nucleus and chromatin. The nuclei of untreated and con-
trol cells were spherical and ﬂuoresced uniformly, and the chromatin
was intact. The cells treated with 24 h IC50 concentration of 1-AHAQ
showed changes in the morphology of their nuclei such as chromatin
marginalization, condensation and fragmentation. Fig. 10 indicates
the apoptotic nuclear morphologies as brought up by 1-AHAQ-mide staining. (a) Representative morphological changes observed against MDAMB
changes was determined and classiﬁed into three categories: viable, apoptosis and
Fig. 10. The effect of 1-AHAQ on MDAMB 231 cells with Hoechst staining. (a) Representative morphological changes observed against MDAMB 231 cells after 24 h incubation
with 1-AHAQ. (b) Relative percentage of morphological changes was determined and classiﬁed into two categories: Normal and abnormal nuclei as compared with the
control cells after 24h incubation.
P. Mondal et al. / Biochemistry and Biophysics Reports 4 (2015) 312–323322treatment. At the concentration of 1-AHAQ that kills 50% of cells, 46%
had abnormal nuclei. Considering the overall perspective of the
apoptotic effect of 1-AHAQ on MDA-MB-231 breast adinocarcinoma
cells and its mode of action therein one may suggest that the less
expensive 1-AHAQ may be used as an affordable alternative to the
very expensive anthracycline drugs in the near future.4. Conclusions
The single crystal structure of 1-AHAQ, an analogue of anthracy-
cline drugs, was evaluated in the present study. The outcome is a
valuable addition in the area of structure and bonding of anthracy-
clines as there are not many reports in this area. The geometry of the
molecule was optimized by computational methods that correlate
well with the single crystal structure. Geometrical parameters ob-
tained from both the computational and experimental results were
found to be in a rational agreement. Two types of hydrogen bonds
were observed in the molecule as established by X-ray diffraction
study, DFT and NBO analysis. The theoretical vibrational spectra of
the molecule studied by VEDA by using PED analysis, corroborates
with the experimental values excellently. Theoretical studies on vi-
brational and molecular spectra determined the mode of vibration
and transitions involved. The electrochemical study showed that
1-AHAQ undergoes quasi-reversible single step reduction involving
two electrons in aqueous solution at physiological pH (7.4) like an-
thracycline anticancer drugs. The molecule has a signiﬁcant afﬁnity
for binding DNA and it intercalates into DNA base pairs through its
planar 9,10-anthraquinone unit. It induces apoptosis in MDA-MB-231
breast adinocarcinoma cells while its cytotxicity to the HBL-100
normal breast epithelial cell is ignorable. The electrochemical as-
pects, structural characteristics and the afﬁnity of the molecule to
interact with DNA possibly play role in its action as a potential an-
titumor agent.Conﬂict of interest
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